Skip to Content

Nektar Therapeutics NKTR Stock Quote

| Rating as of

Morningstar‘s Stock Analysis NKTR

There is no Morningstar’s Analysis data available.

Key Statistics NKTR

Company Profile NKTR

Business Description

Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, the company is focused on activating the immune system's natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.

Contact
455 Mission Bay Boulevard South
San Francisco, CA, 94158
T +1 415 482-5300
Industry Biotechnology
Most Recent Earnings Jun 30, 2022
Fiscal Year End Dec 31, 2022
Stock Type Slow Growth
Employees 225

Related News NKTR